118 related articles for article (PubMed ID: 27783563)
1. Combinations of targeted therapies in human cancers.
Decaudin D; Le Tourneau C
Aging (Albany NY); 2016 Oct; 8(10):2258-2259. PubMed ID: 27783563
[No Abstract] [Full Text] [Related]
2. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
[TBL] [Abstract][Full Text] [Related]
3. Combining molecular targeted therapies: clinical experience.
Pivot X; Bedairia N; Thiery-Vuillemin A; Espie M; Marty M
Anticancer Drugs; 2011 Sep; 22(8):701-10. PubMed ID: 21467916
[TBL] [Abstract][Full Text] [Related]
4. Cancer therapy: an evolved approach.
Willyard C
Nature; 2016 Apr; 532(7598):166-8. PubMed ID: 27075079
[No Abstract] [Full Text] [Related]
5. Molecular-targeted agents combination therapy for cancer: developments and potentials.
Li F; Zhao C; Wang L
Int J Cancer; 2014 Mar; 134(6):1257-69. PubMed ID: 23649791
[TBL] [Abstract][Full Text] [Related]
6. [Combination therapy of targeted drugs].
Saijo N
Nihon Rinsho; 2012 Nov; 70 Suppl 8():652-7. PubMed ID: 23513917
[No Abstract] [Full Text] [Related]
7. New research shows why advanced cancers recur after targeted treatments.
Printz C
Cancer; 2012 Oct; 118(20):4913. PubMed ID: 23042616
[No Abstract] [Full Text] [Related]
8. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
9. Combining targeted drugs to stop resistant tumors.
Kaiser J
Science; 2011 Mar; 331(6024):1542-5. PubMed ID: 21436437
[No Abstract] [Full Text] [Related]
10. A systems biology approach to personalizing therapeutic combinations.
Kwong LN; Heffernan TP; Chin L
Cancer Discov; 2013 Dec; 3(12):1339-44. PubMed ID: 24327696
[TBL] [Abstract][Full Text] [Related]
11. Combinations go on trial.
Delude C
Cancer Discov; 2012 Jan; 2(1):8. PubMed ID: 22585151
[No Abstract] [Full Text] [Related]
12. Targeted therapy for triple-negative breast cancer: where are we?
Duffy MJ; McGowan PM; Crown J
Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
[TBL] [Abstract][Full Text] [Related]
13. New therapy targets resistant non-small-cell lung cancers.
Jenks S
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421346
[No Abstract] [Full Text] [Related]
14. Preclinical modeling of combination treatments: fantasy or requirement?
Decker S; Sausville EA
Ann N Y Acad Sci; 2005 Nov; 1059():61-9. PubMed ID: 16382044
[TBL] [Abstract][Full Text] [Related]
15. Development of Molecularly Driven Targeted Combination Strategies.
Yap TA; Rodon J
Oncologist; 2017 Dec; 22(12):1421-1423. PubMed ID: 29038233
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Crystal AS; Shaw AT; Sequist LV; Friboulet L; Niederst MJ; Lockerman EL; Frias RL; Gainor JF; Amzallag A; Greninger P; Lee D; Kalsy A; Gomez-Caraballo M; Elamine L; Howe E; Hur W; Lifshits E; Robinson HE; Katayama R; Faber AC; Awad MM; Ramaswamy S; Mino-Kenudson M; Iafrate AJ; Benes CH; Engelman JA
Science; 2014 Dec; 346(6216):1480-6. PubMed ID: 25394791
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trials.
Burris HA
Ann Pharmacother; 1994 May; 28(5 Suppl):S7-10. PubMed ID: 7915158
[No Abstract] [Full Text] [Related]
18. [The HER3/ERBB3 receptor: the dark side of the ERBB planet].
Larbouret C; Gaborit N; Poul MA; Pèlegrin A; Chardès T
Med Sci (Paris); 2015 May; 31(5):465-8. PubMed ID: 26059291
[No Abstract] [Full Text] [Related]
19. High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come.
Scarlett UK; Chang DC; Murtagh TJ; Flaherty KT
Cancer Discov; 2016 Sep; 6(9):956-62. PubMed ID: 27587468
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? The significant impact of chemotherapy in lung cancer.
Socinski MA
Clin Adv Hematol Oncol; 2014 Nov; 12(11):763, 767-8. PubMed ID: 25674716
[No Abstract] [Full Text] [Related]
[Next] [New Search]
